Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Raltegravir: first in class HIV integrase inhibitor

Authors Temesgen Z, Siraj DS

Published 11 April 2008 Volume 2008:4(2) Pages 493—500

DOI https://doi.org/10.2147/TCRM.S2268


Zelalem Temesgen1, Dawd S Siraj2

1Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USA

Abstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

Keywords: raltegravir, HIV, antiretroviral agents, integrase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]